ADMA Biologics Inc
ADMA Healthcare Biotechnology
ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024. In the quarter to June 2026, revenue grew 1.98%, EPS grew 21.4%, free cash flow grew 19.7% and total debt rose 140.5%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow ADMA
ADMA Biologics Inc (ADMA) Piotroski F-score
ADMA Biologics Inc's Piotroski F-score for fiscal 2025 is 5 out of 9: 5 of nine tests of profitability, leverage and efficiency passed, down from 7 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 5 | (2.00) |
| FY2024 | 7 | 1.00 |
| FY2023 | 6 | 1.00 |
| FY2022 | 5 | 1.00 |
| FY2021 | 4 | 2.00 |
| FY2020 | 2 | (2.00) |
| FY2019 | 4 | 2.00 |
| FY2018 | 2 | (1.00) |
| FY2017 | 3 | (1.00) |
| FY2016 | 4 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | 26.40% | 48.34% | Pass | 1 |
| Positive operating cash flow | 50.40m | 118.67m | Pass | 1 |
| Rising return on assets | 26.40% | 48.34% | Fail | 0 |
| Cash flow above net income | (96.53m) | (79.00m) | Fail | 0 |
| Falling long-term leverage | 0.14 | 0.20 | Pass | 1 |
| Rising current ratio | 6.71 | 5.97 | Pass | 1 |
| No new shares issued | 238,299,000 | 233,084,000 | Fail | 0 |
| Rising gross margin | 57.39% | 51.48% | Pass | 1 |
| Rising asset turnover | 0.92 | 1.04 | Fail | 0 |
| Piotroski F-score | Mixed | 5 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | 8 |
| HRMY Harmony Biosciences Holdings, Inc. compare | 5 |
| ADMA ADMA Biologics Inc | 5 |
| BEAM Beam Therapeutics Inc. compare | 4 |
| PGEN Precigen, Inc. compare | 3 |
| NAMS NewAmsterdam Pharma Company N.V. compare | 3 |
| CLDX Celldex Therapeutics, Inc. compare | 2 |
| SLS SELLAS Life Sciences Group, Inc. compare | 2 |
| MBX MBX Biosciences, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover